Document Detail


Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema.
MedLine Citation:
PMID:  21765371     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To compare the efficacy and safety of intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema.
METHODS: Thirty-two eyes with diffuse diabetic macular edema were randomly allocated to intravitreal injection of 4 mg/0.1 mL of triamcinolone (Group 1: N = 16) or 500 μg/0.1 mL of diclofenac (Group 2: N = 16). Preoperative and postoperative visual acuity, intraocular pressure, and central macular thickness were recorded and compared between the 2 groups up to 12 weeks.
RESULTS: Both groups showed statistically significant reduction in central macular thickness (triamcinolone: P = 0.02 and diclofenac: P = 0.01), without statistically significant difference between the 2 groups. Visual improvement was significant only in triamcinolone group (P = 0.05). However, the 2 groups showed no statistically significant difference in mean visual acuity or mean line improvement. Transient elevation of intraocular pressure occurred in 12.5% of the triamcinolone group. Diclofenac group showed statistically significant reduced intraocular pressure (P = 0.02).
CONCLUSION: Intravitreal diclofenac is effective in the treatment of diffuse diabetic macular edema up to 12 weeks. Intravitreal triamcinolone and diclofenac appear to have comparable therapeutic effects on retinal thickness. The degree of visual improvement is higher with triamcinolone.
Authors:
Amal M Elbendary; Maha M Shahin
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Retina (Philadelphia, Pa.)     Volume:  31     ISSN:  1539-2864     ISO Abbreviation:  Retina (Philadelphia, Pa.)     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-10-26     Completed Date:  2012-02-24     Revised Date:  2012-06-05    
Medline Journal Info:
Nlm Unique ID:  8309919     Medline TA:  Retina     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2058-64     Citation Subset:  IM    
Affiliation:
Mansoura Ophthalmic Center, Mansoura University, Mansoura, Egypt. amalelbendary67@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-Inflammatory Agents, Non-Steroidal / adverse effects,  therapeutic use*
Diabetic Retinopathy / drug therapy*,  physiopathology
Diclofenac / adverse effects,  therapeutic use*
Female
Glucocorticoids / adverse effects,  therapeutic use*
Humans
Intraocular Pressure / physiology
Intravitreal Injections
Macula Lutea / pathology
Macular Edema / drug therapy*,  physiopathology
Male
Middle Aged
Tomography, Optical Coherence
Treatment Outcome
Triamcinolone Acetonide / adverse effects,  therapeutic use*
Visual Acuity / physiology
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Glucocorticoids; 15307-86-5/Diclofenac; 76-25-5/Triamcinolone Acetonide
Comments/Corrections
Comment In:
Retina. 2012 May;32(5):1033; author reply 1033-4   [PMID:  22495330 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Placido-Based Indices of Corneal Irregularity.
Next Document:  INCIDENCE OF, RISK FACTORS FOR, AND COMBINED MECHANISM OF LATE-ONSET OPEN-ANGLE GLAUCOMA AFTER VITRE...